Clinical Trials

Isarna Therapeutics dedicates itself to developing new therapies to improve patient outcomes with ophthalmic, fibrotic, or oncologic diseases.

Advanced Glaucoma / ISTH0036:

Phase 1 trial with ISTH0036 in patients with advanced glaucoma set to undergo trabeculectomy has recently been completed.


Phase 2a trials in AMD, DME and further retina indications are currently under preparation.

For more information, please visit the US National Institutes of Health’s clinical trials registration website


Please note:
ISTH0036 is a compound undergoing clinical development. ISTH0036’s use is restricted to patients enrolled in Isarna-sponsored clinical studies. The compound is not available for any other usage.